OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Check out the latest features and columns!
These five brands prove that pharma marketers can pull it together with compelling stories, and meaningful patient impact, even during a pandemic.
October's Executive Profile features Imvax CEO John Furey
Biopharma leaders and experts gather to discuss the future of pharma collaboration and tackling critical public health needs—together.
Pharm Exec’s latest listing of the top global biopharma sales producers captures the critical business and public health balancing act that was required in the Year of COVID.
Read the profiles of 13 diverse leaders vital to the future of the biopharma industry.
With a complicated and challenging global picture greeting the new year, driven by the continuing pandemic and historic political and regulatory changes in the US and Europe, we outline eight diverse trends critical to biopharma’s future health and growth.
October 12, 2021
Adweek first published its list of Fastest-Growing Agencies in 2019.
How can large pharma improve D&I in its companies?
Evaluating patient data in the context of complementary information can provide comprehensive market insights for product strategy.
COVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.
Our latest numbers crunch on biopharma financial performance—this one assessing growth and value-generation during the heart of COVID-19—reveals a mix of the familiar and new entrants into the top spots in seven business-critical metrics.
New methods and policies necessitated by the global pandemic are slated to become permanent fixtures in FDA enforcement and regulatory programs.
Unconventional collaborations between biopharma and tech are starting to take off.
While there is broad agreement that the Chief Data Officer plays a critical part in pharma, a definitive description of the role is still evolving.
Imvax CEO John Furey taps into tried-and-true powers of hope and clarity as he moves the clinical stage biotech from single program to platform company.
While Q3 numbers look bleak, is improvement on the horizon?